Portfolio Company · Operating Co.

Amicus Therapeutics

Healthcare · Website

backed byCanaan Partners

CurrentHealthcare

Amicus Therapeutics

a portfolio company of

Canaan Partners

Status on record: Current

PE Firm Index

Who owns Amicus Therapeutics?

Amicus Therapeutics is listed as a current portfolio company of Canaan Partners on Canaan Partners' own portfolio page.

From the company's website

Redefining Expectations in Rare Disease About Amicus Amicus is a wholly owned subsidiary of BioMarin Pharmaceutical Inc., a leading, global rare disease biotechnology company focused on delivering medicines for people living with genetically defined conditions.

Source: amicusrx.com, read November 2026

Company Snapshot

Amicus Therapeutics is a Healthcare company. Its owner on record, Canaan Partners, is a firm. Canaan Partners lists 349 companies in the index, 17 of them in Healthcare.

SectorHealthcare

Parent PE firmCanaan Partners

Ownership statusCurrent

WebsiteVisit ↗

About the owner

Canaan Partners

Companies in the index: 349

Venture capital firm investing across technology and healthcare.

Read the Canaan Partners profile

Questions about Amicus Therapeutics

Who owns Amicus Therapeutics?

Amicus Therapeutics is listed as a current portfolio company of Canaan Partners on Canaan Partners' own portfolio page.

What sector is Amicus Therapeutics in?

Amicus Therapeutics is in Healthcare. Classified from the company's own description.

What else does Canaan Partners own in Healthcare?

Canaan Partners lists 16 other Healthcare companies in the index, including Acesion Pharma ApS, Agomab Therapeutics, Alphina Therapeutics, Alterome Therapeutics, Inc. and Antiva Biosciences.

What is Amicus Therapeutics' website?

Amicus Therapeutics' website is https://amicusrx.com/.

Sources

Canaan Partners' page on Amicus Therapeutics
Canaan Partners
https://canaan.com/companies

This profile is based on publicly available information and may be incomplete or outdated. PE Firm Index is not affiliated with Amicus Therapeutics and does not provide investment advice.

Other portfolio companies of Canaan Partners

6 of 348 shown

Abyrx

Aceiss

Acesion Pharma ApS

Actio Biosciences, Inc.

ACTIVE Network

ActualyzeAI, Inc.

See the full Canaan Partners portfolio.

Other Healthcare companies held by Canaan Partners

Acesion Pharma ApS

Alphina Therapeutics

Alterome Therapeutics, Inc.Antiva Biosciences

DexCom

Diligent Robotics

Other Healthcare portfolio companies

via Wavemaker 360 Health

3P Biopharmaceuticals

via Marlin Equity Partners

Browse PE-backed companies.

Is this your company?

Claiming is free and reviewed by hand. Correct facts and add your team.

Claim this profile Suggest a correction

Ownership

Parent PE firm

Canaan Partners

Status: Current

Check this company's website

Check this company's website now

Free, in about two minutes: the verified issues a buyer or a customer's browser would meet. Runs on GTM Brain, by DevriX.

Observational measurements of this company's public website only. Not a rating of the company, its performance, its management, or its investment merit. Not investment advice. Request a correction or removal via Submit Update.

For PE-backed companies

DevriX

DevriX runs the websites, integrations and data that bring in revenue, as one accountable engineering and operations team, through acquisitions and exit.

Where DevriX helps

Value creation through the holdRevenue, data, web and AI run as one operating cadence, tied to EBITDA.Add-ons and carve-outsConsolidate or separate platforms and unify reporting after a deal.Exit readinessFind the technology and data issues a buyer's diligence would raise, before it does.

Send DevriX a short brief

A short form on devrix.com. No call to book.

Disclosure: PE Firm Index is maintained by Mario Peshev, who founded and runs DevriX. DevriX listing

Weekly PE M&A and market research, by email

The Growth Shuttle Insider is Mario Peshev's weekly newsletter for PE owners and operators. Each issue carries the week's private equity deals from this index, market data and research, and an essay from Mario.

Free. One email a week. Unsubscribe from any issue. Your address goes to beehiiv, the service that sends the Insider.

Research

The 2027 Digital Value Creation Baseline

1,407 PE-backed companies from 179 sponsors, measured from public sources in October 2026. 15% of service and product companies have the full path from search to CRM.

Read the research

Research by Growth Shuttle and DevriX.